文献速递炎症性肠病

炎症性肠病患者中的阿片类药物使用:系统综述与荟萃分析

Opioid Use Among Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-08-21

该系统综述与荟萃分析检索MEDLINE、Embase、Web of Science和Cochrane Library至2019年11月,纳入31项研究,发现炎症性肠病(IBD)门诊患者阿片类药物使用率为21%(95%CI 13%-30%),住院患者为62%(95%CI 25%-92%);使用与女性、抑郁、物质滥用、既往胃肠手术、生物制剂和激素使用相关,并与IBD活动度增加、医疗使用、感染和死亡率相关。

要点

  • IBD门诊患者阿片类药物使用率为21%(95%CI 13%-30%),住院患者为62%(95%CI 25%-92%)。
  • 阿片使用与女性(RR 1.20)、抑郁(RR 1.99)、物质滥用(RR 4.67)、既往胃肠手术(RR 2.33)、生物制剂(RR 1.36)和激素使用(RR 1.41)相关。
  • 系统综述显示阿片使用似乎与IBD活动度增加、医疗使用、感染和死亡率相关;需进一步研究确定因果关系。

核心结论

  • 系统综述与荟萃分析发现21%的IBD门诊患者和62%的住院患者使用阿片类药物,使用与更严重的IBD和医疗使用增加相关。
  • 需进一步研究确定阿片类药物是这些关联的原因还是结果,但仍需紧急干预以减少阿片使用、改善疾病相关结局并降低医疗费用。

研究设计与样本

  • 系统检索MEDLINE、Embase、Web of Science和Cochrane Library截至2019年11月,共识别780条引文,最终纳入31项研究。
  • 采用随机效应荟萃分析估计合并相对危险度(RR)和95%CI,并使用纽卡斯尔-渥太华量表评估质量。

主要发现

  • 门诊IBD患者阿片类药物使用率为21%(95%CI 13%-30%),住院IBD患者为62%(95%CI 25%-92%)。
  • 阿片使用与女性(RR 1.20;95%CI 1.03-1.40)、抑郁(RR 1.99;95%CI 1.80-2.19)、物质滥用(RR 4.67;95%CI 2.87-7.60)相关。
  • 阿片使用与既往胃肠手术(RR 2.33;95%CI 1.66-3.26)、生物制剂使用(RR 1.36;95%CI 1.06-1.74)和激素使用(RR 1.41;95%CI 1.04-1.91)相关。
  • 基于系统综述,阿片使用似乎还与IBD活动度增加、医疗使用、感染和死亡率相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需进一步研究以确定阿片类药物是这些关联的原因还是结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Despite reported adverse effects of opioids in patients with inflammatory bowel disease (IBD), the burden of opioid use in this population appears to be high. We performed a systematic review and meta-analysis of prior studies to determine the prevalence of opioid use among patients with IBD as well as risk factors and outcomes associated with opioid use in this population. METHODS: We conducted a systematic search of MEDLINE, Embase, Web of Science, and the Cochrane Library through November of 2019. Primary outcomes included the prevalence of opioid use and demographic and clinical variables associated with opioid use in patients with IBD. Quality was assessed using the Newcastle-Ottawa scale. We used random-effect meta-analysis to estimate pooled relative risks (RRs) and 95% CIs. RESULTS: Of 780 citations identified, 31 were included in our study. The prevalence of opioid use was 21% (95% CI, 13%-30%) in the outpatient setting. Likewise, 62% (95% CI, 25%-92%) of patients received opioids while hospitalized for IBD. Opioid use was associated with female sex (RR 1.20; 95% CI 1.03-1.40), depression (1.99; 95% CI 1.80-2.19), substance abuse (4.67; 95% CI 2.87-7.60), prior gastrointestinal surgery (2.33; 95% CI 1.66-3.26), biologic use (1.36; 95% CI 1.06-1.74), and steroid use (1.41; 95% CI 1.04-1.91). Based on the systematic review, opioid use also appeared to be associated with increased IBD activity, healthcare use, infection, and mortality. CONCLUSION: In a systematic review and meta-analysis, we found that 21% of outpatients with IBD (and 62% of hospitalized patients) are opioid users; use is associated with more severe IBD and increased healthcare use. Further studies are required to determine whether opioids are the cause or an effect of these associations. Nonetheless, urgent interventions are needed to reduce opioid use, improve disease-related outcomes and reduce healthcare costs.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Niccum B, Moninuola O, Miller K, et al. Opioid Use Among Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2020. PMID: 32835841. doi:10.1016/j.cgh.2020.08.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。